Categories
Change Password!
Reset Password!
Subcutaneous semaglutide therapy markedly improves glycemic control while promoting substantial reductions in body weight and BMI among patients with type 2 diabetes mellitus.
In a real-world clinical study, semaglutide remarkably improved both glycemic control and body weight among patients with type 2 diabetes mellitus (T2DM). This study led by Petya Milushewa et al. aimed to identify clinical factors linked to reductions in glycated haemoglobin (HbA1c) and body weight in patients receiving semaglutide as part of routine diabetes care in Bulgaria.
Overall, 168 adults with T2DM who were under continuous dispensary monitoring at the endocrinology center were enrolled. Participants were initiated on subcutaneous semaglutide at a starting dose of 0.25 mg weekly, increased to 0.5 mg after 4 weeks, and titrated to a maintenance dose of 1 mg weekly for one year. Clinical and biochemical parameters, including HbA1c, weight, body mass index (BMI), and comorbidities, were assessed at baseline and after 12 months of treatment.
At baseline, 92.3% of patients were classified as obese (BMI ≥30 kg/m²), with 53.6% in Obesity Class I. After 1 year of GLP-1 receptor agonist therapy, notable metabolic improvements were achieved:
Importantly, 81 patients transitioned to a lower obesity class, while only 15 remained in Class III obesity. The findings of this retrospective analysis reaffirm semaglutide’s role as a potent dual-action therapy for tackling both hyperglycemia and obesity in T2DM sufferers. The study emphasizes that structured follow-up under endocrinologist supervision, as mandated by Bulgaria’s national diabetes management protocols, can further optimize treatment outcomes. Researchers advocate for long-term prospective studies to explore the durability of these benefits and to find out patient-specific predictors of favorable therapeutic response.
Frontiers in Endocrinology
Predictive factors for HbA1c and weight loss associated with semaglutide treatment in type 2 diabetes mellitus: real-world clinical evidence
Petya Milushewa et al.
Comments (0)